| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 83 | 2025 | 1260 | 13.030 |
Why?
|
| HIV Infections | 101 | 2025 | 5097 | 9.190 |
Why?
|
| Infectious Disease Transmission, Vertical | 34 | 2025 | 472 | 6.040 |
Why?
|
| Receptors, IgG | 10 | 2022 | 28 | 4.610 |
Why?
|
| Receptors, CCR5 | 14 | 2024 | 54 | 4.580 |
Why?
|
| Haplotypes | 21 | 2025 | 125 | 4.330 |
Why?
|
| Humans | 159 | 2025 | 14537 | 3.630 |
Why?
|
| Polymorphism, Single Nucleotide | 15 | 2021 | 198 | 3.420 |
Why?
|
| Genetic Variation | 18 | 2025 | 175 | 3.100 |
Why?
|
| Killer Cells, Natural | 13 | 2024 | 52 | 2.990 |
Why?
|
| CD4-Positive T-Lymphocytes | 14 | 2024 | 151 | 2.940 |
Why?
|
| Viral Load | 30 | 2025 | 819 | 2.920 |
Why?
|
| Alleles | 18 | 2025 | 143 | 2.870 |
Why?
|
| Female | 80 | 2025 | 9103 | 2.820 |
Why?
|
| HLA-C Antigens | 6 | 2021 | 15 | 2.730 |
Why?
|
| Anti-HIV Agents | 16 | 2025 | 1324 | 2.530 |
Why?
|
| Gene Frequency | 17 | 2023 | 122 | 2.260 |
Why?
|
| South Africa | 62 | 2024 | 7596 | 2.220 |
Why?
|
| Adult | 54 | 2024 | 5913 | 2.150 |
Why?
|
| HIV Seropositivity | 12 | 2024 | 265 | 2.100 |
Why?
|
| Male | 49 | 2025 | 6754 | 2.070 |
Why?
|
| Receptors, KIR | 6 | 2019 | 23 | 1.980 |
Why?
|
| INDEL Mutation | 6 | 2019 | 16 | 1.960 |
Why?
|
| Interleukin-8 | 9 | 2021 | 21 | 1.950 |
Why?
|
| DNA, Viral | 19 | 2022 | 165 | 1.860 |
Why?
|
| Antigens, CD | 7 | 2024 | 26 | 1.810 |
Why?
|
| CD8-Positive T-Lymphocytes | 11 | 2024 | 48 | 1.780 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2019 | 16 | 1.760 |
Why?
|
| Genotype | 16 | 2023 | 442 | 1.730 |
Why?
|
| Infant | 32 | 2024 | 2244 | 1.630 |
Why?
|
| Chemokines, CC | 7 | 2010 | 15 | 1.630 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2021 | 176 | 1.610 |
Why?
|
| Neutrophils | 10 | 2004 | 53 | 1.580 |
Why?
|
| Chemokine CCL3 | 6 | 2013 | 23 | 1.570 |
Why?
|
| Anti-Retroviral Agents | 10 | 2025 | 551 | 1.530 |
Why?
|
| Case-Control Studies | 14 | 2022 | 480 | 1.500 |
Why?
|
| Infant, Newborn | 25 | 2024 | 1479 | 1.450 |
Why?
|
| Receptors, CXCR4 | 6 | 2013 | 28 | 1.430 |
Why?
|
| T-Lymphocytes | 6 | 2024 | 65 | 1.420 |
Why?
|
| Pregnancy Complications, Infectious | 14 | 2024 | 529 | 1.390 |
Why?
|
| Gene Dosage | 6 | 2014 | 23 | 1.390 |
Why?
|
| Liver Transplantation | 3 | 2019 | 55 | 1.370 |
Why?
|
| HLA Antigens | 8 | 2022 | 50 | 1.330 |
Why?
|
| HLA-DP beta-Chains | 2 | 2019 | 4 | 1.320 |
Why?
|
| Cytokines | 12 | 2023 | 107 | 1.320 |
Why?
|
| Disease Resistance | 2 | 2021 | 6 | 1.320 |
Why?
|
| HLA-B Antigens | 4 | 2017 | 12 | 1.310 |
Why?
|
| Viremia | 4 | 2024 | 66 | 1.290 |
Why?
|
| Pregnancy | 21 | 2024 | 1862 | 1.260 |
Why?
|
| RNA, Viral | 12 | 2021 | 303 | 1.250 |
Why?
|
| Polymorphism, Genetic | 7 | 2020 | 99 | 1.240 |
Why?
|
| CD4 Lymphocyte Count | 18 | 2023 | 656 | 1.230 |
Why?
|
| HLA-A Antigens | 3 | 2017 | 7 | 1.220 |
Why?
|
| Genetics, Population | 4 | 2021 | 52 | 1.150 |
Why?
|
| HIV Antibodies | 4 | 2019 | 247 | 1.130 |
Why?
|
| Middle Aged | 20 | 2021 | 3601 | 1.110 |
Why?
|
| Tuberculosis, Pulmonary | 11 | 2022 | 324 | 1.100 |
Why?
|
| Nevirapine | 5 | 2019 | 146 | 1.080 |
Why?
|
| Linkage Disequilibrium | 10 | 2021 | 40 | 1.070 |
Why?
|
| Adenoviruses, Human | 10 | 1996 | 11 | 1.010 |
Why?
|
| Disease Susceptibility | 3 | 2021 | 46 | 0.990 |
Why?
|
| Young Adult | 12 | 2024 | 2498 | 0.960 |
Why?
|
| Polymerase Chain Reaction | 10 | 2017 | 260 | 0.950 |
Why?
|
| Chemoprevention | 2 | 2018 | 33 | 0.940 |
Why?
|
| Leukocytes, Mononuclear | 8 | 2023 | 60 | 0.940 |
Why?
|
| Living Donors | 3 | 2019 | 20 | 0.940 |
Why?
|
| AIDS Vaccines | 3 | 2021 | 152 | 0.910 |
Why?
|
| Sequence Analysis, DNA | 10 | 2021 | 181 | 0.900 |
Why?
|
| Child | 21 | 2025 | 2242 | 0.890 |
Why?
|
| Disease Progression | 11 | 2019 | 154 | 0.890 |
Why?
|
| 3' Untranslated Regions | 3 | 2019 | 9 | 0.880 |
Why?
|
| Lactobacillus | 3 | 2018 | 7 | 0.860 |
Why?
|
| Tuberculosis | 7 | 2025 | 543 | 0.850 |
Why?
|
| Receptors, KIR2DL1 | 2 | 2021 | 5 | 0.840 |
Why?
|
| Recombination, Genetic | 4 | 2019 | 27 | 0.810 |
Why?
|
| Withholding Treatment | 2 | 2019 | 26 | 0.780 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2021 | 4 | 0.760 |
Why?
|
| Cohort Studies | 12 | 2021 | 967 | 0.730 |
Why?
|
| Viral Proteins | 3 | 2010 | 30 | 0.730 |
Why?
|
| Receptors, Chemokine | 2 | 2017 | 6 | 0.710 |
Why?
|
| DNA Copy Number Variations | 3 | 2021 | 22 | 0.710 |
Why?
|
| Bacteriophages | 2 | 2010 | 4 | 0.700 |
Why?
|
| HIV | 5 | 2024 | 380 | 0.700 |
Why?
|
| Receptors, Virus | 2 | 2017 | 5 | 0.690 |
Why?
|
| Mycobacterium tuberculosis | 7 | 2022 | 329 | 0.680 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 11 | 0.670 |
Why?
|
| Urinary Tract | 1 | 2019 | 4 | 0.660 |
Why?
|
| Africa South of the Sahara | 8 | 2025 | 353 | 0.650 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2019 | 7 | 0.650 |
Why?
|
| Liver Failure | 1 | 2018 | 5 | 0.620 |
Why?
|
| Aged | 9 | 2020 | 1740 | 0.620 |
Why?
|
| Cell Degranulation | 4 | 2004 | 7 | 0.620 |
Why?
|
| Flow Cytometry | 10 | 2024 | 67 | 0.600 |
Why?
|
| Virus Latency | 2 | 2017 | 5 | 0.600 |
Why?
|
| Chemokine CCL4 | 3 | 2014 | 14 | 0.590 |
Why?
|
| HIV Antigens | 3 | 2007 | 26 | 0.590 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 3 | 2004 | 9 | 0.590 |
Why?
|
| Molecular Sequence Data | 16 | 2014 | 263 | 0.580 |
Why?
|
| Lymphocyte Activation | 8 | 2019 | 40 | 0.570 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2022 | 48 | 0.560 |
Why?
|
| Mothers | 7 | 2020 | 195 | 0.550 |
Why?
|
| GTPase-Activating Proteins | 1 | 2017 | 3 | 0.550 |
Why?
|
| Chemokine CXCL12 | 3 | 2013 | 4 | 0.530 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2009 | 187 | 0.520 |
Why?
|
| Monocytes | 5 | 2021 | 27 | 0.520 |
Why?
|
| Virus Replication | 7 | 2011 | 88 | 0.510 |
Why?
|
| Whole Genome Sequencing | 3 | 2021 | 44 | 0.510 |
Why?
|
| Fetal Blood | 6 | 2007 | 27 | 0.500 |
Why?
|
| Plasmids | 2 | 2018 | 23 | 0.500 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2014 | 90 | 0.500 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2015 | 15 | 0.490 |
Why?
|
| Silver | 1 | 2015 | 15 | 0.490 |
Why?
|
| Vagina | 2 | 2018 | 91 | 0.490 |
Why?
|
| Alginates | 1 | 2015 | 34 | 0.490 |
Why?
|
| Herpesvirus 2, Human | 1 | 2015 | 43 | 0.490 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 57 | 0.480 |
Why?
|
| HLA-G Antigens | 1 | 2014 | 3 | 0.480 |
Why?
|
| Pharmacogenetics | 3 | 2025 | 31 | 0.480 |
Why?
|
| Drug Carriers | 1 | 2015 | 93 | 0.480 |
Why?
|
| Hypersensitivity | 1 | 2014 | 7 | 0.470 |
Why?
|
| Biomarkers | 5 | 2024 | 327 | 0.460 |
Why?
|
| Base Sequence | 11 | 2014 | 149 | 0.450 |
Why?
|
| Cross-Sectional Studies | 9 | 2024 | 1422 | 0.440 |
Why?
|
| Interferon-gamma | 5 | 2017 | 39 | 0.440 |
Why?
|
| Age Factors | 6 | 2018 | 370 | 0.430 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2015 | 472 | 0.430 |
Why?
|
| Prospective Studies | 9 | 2024 | 1160 | 0.430 |
Why?
|
| Cell Membrane | 1 | 2013 | 10 | 0.420 |
Why?
|
| Signal Transduction | 1 | 2013 | 33 | 0.410 |
Why?
|
| Immunity, Cellular | 5 | 2019 | 25 | 0.410 |
Why?
|
| Genome, Viral | 6 | 2009 | 64 | 0.410 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 7 | 0.410 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 36 | 0.400 |
Why?
|
| DNA | 6 | 2024 | 73 | 0.390 |
Why?
|
| Cryptococcus | 2 | 2023 | 10 | 0.380 |
Why?
|
| HIV Long-Term Survivors | 3 | 2021 | 8 | 0.380 |
Why?
|
| Child, Preschool | 10 | 2018 | 1748 | 0.380 |
Why?
|
| Meningitis, Cryptococcal | 2 | 2023 | 16 | 0.380 |
Why?
|
| Lymphocyte Subsets | 2 | 2019 | 6 | 0.380 |
Why?
|
| Receptors, Complement | 2 | 2001 | 3 | 0.370 |
Why?
|
| Complement C5a | 2 | 2001 | 3 | 0.370 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 52 | 0.360 |
Why?
|
| NF-kappa B | 3 | 2017 | 16 | 0.360 |
Why?
|
| Lysogeny | 1 | 2010 | 2 | 0.360 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2017 | 6 | 0.360 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2010 | 3 | 0.350 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 3 | 0.350 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2010 | 4 | 0.350 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 5 | 0.350 |
Why?
|
| Genetic Engineering | 1 | 2010 | 7 | 0.350 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 3 | 0.350 |
Why?
|
| Gene Expression Regulation | 4 | 2017 | 40 | 0.340 |
Why?
|
| Sensitivity and Specificity | 5 | 2024 | 385 | 0.340 |
Why?
|
| Epitopes | 3 | 2007 | 97 | 0.330 |
Why?
|
| Genetic Association Studies | 2 | 2019 | 11 | 0.330 |
Why?
|
| Histocompatibility Testing | 2 | 2019 | 26 | 0.330 |
Why?
|
| Drug Resistance, Viral | 2 | 2024 | 278 | 0.320 |
Why?
|
| Interleukin-2 | 3 | 2017 | 22 | 0.320 |
Why?
|
| L-Selectin | 3 | 2006 | 7 | 0.310 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2020 | 73 | 0.300 |
Why?
|
| Leukocytes | 3 | 2004 | 14 | 0.290 |
Why?
|
| Human Genome Project | 2 | 2018 | 7 | 0.290 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2019 | 36 | 0.290 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2007 | 7 | 0.280 |
Why?
|
| Cells, Cultured | 9 | 2007 | 79 | 0.280 |
Why?
|
| Gene Duplication | 2 | 2022 | 13 | 0.280 |
Why?
|
| India | 2 | 2017 | 62 | 0.280 |
Why?
|
| Receptors, Interleukin-8A | 3 | 2004 | 4 | 0.280 |
Why?
|
| Receptors, Interleukin-8B | 3 | 2004 | 4 | 0.280 |
Why?
|
| Risk Factors | 4 | 2021 | 1475 | 0.270 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2007 | 40 | 0.270 |
Why?
|
| Chemokines, CXC | 2 | 2003 | 2 | 0.270 |
Why?
|
| Time Factors | 5 | 2019 | 507 | 0.270 |
Why?
|
| Lymphocytes | 3 | 2001 | 20 | 0.270 |
Why?
|
| Phytohemagglutinins | 3 | 2021 | 9 | 0.260 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2006 | 18 | 0.260 |
Why?
|
| Amino Acid Sequence | 9 | 2007 | 139 | 0.260 |
Why?
|
| BCG Vaccine | 1 | 2006 | 20 | 0.260 |
Why?
|
| Antigens, Bacterial | 1 | 2006 | 32 | 0.260 |
Why?
|
| Measles virus | 1 | 2005 | 6 | 0.250 |
Why?
|
| Measles | 1 | 2005 | 36 | 0.250 |
Why?
|
| Risk Assessment | 2 | 2024 | 225 | 0.250 |
Why?
|
| Microbiota | 2 | 2023 | 30 | 0.240 |
Why?
|
| Vaginosis, Bacterial | 2 | 2018 | 19 | 0.240 |
Why?
|
| DNA, Bacterial | 2 | 2018 | 53 | 0.240 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2025 | 4 | 0.240 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2025 | 10 | 0.240 |
Why?
|
| Glutathione Transferase | 1 | 2025 | 20 | 0.240 |
Why?
|
| Breast Feeding | 3 | 2020 | 120 | 0.240 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2024 | 3 | 0.240 |
Why?
|
| Lectins, C-Type | 1 | 2024 | 4 | 0.240 |
Why?
|
| Gene Products, env | 2 | 2001 | 11 | 0.240 |
Why?
|
| HIV Integrase | 1 | 2024 | 6 | 0.240 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2024 | 23 | 0.230 |
Why?
|
| Antitubercular Agents | 3 | 2025 | 322 | 0.230 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 112 | 0.230 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 217 | 0.220 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 2004 | 22 | 0.220 |
Why?
|
| Postpartum Period | 1 | 2024 | 85 | 0.220 |
Why?
|
| Early Diagnosis | 2 | 2021 | 82 | 0.220 |
Why?
|
| Rift Valley Fever | 2 | 2015 | 2 | 0.220 |
Why?
|
| Nicotine | 1 | 2023 | 12 | 0.220 |
Why?
|
| Neonatal Screening | 2 | 2021 | 24 | 0.220 |
Why?
|
| Comorbidity | 2 | 2021 | 188 | 0.220 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 101 | 0.220 |
Why?
|
| Genomics | 2 | 2022 | 109 | 0.220 |
Why?
|
| Capsid Proteins | 2 | 1994 | 8 | 0.220 |
Why?
|
| Interleukin-7 | 1 | 2003 | 3 | 0.220 |
Why?
|
| Gene Deletion | 1 | 2003 | 19 | 0.210 |
Why?
|
| HIV Seronegativity | 4 | 2019 | 52 | 0.210 |
Why?
|
| Heterozygote | 1 | 2003 | 43 | 0.210 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2001 | 195 | 0.210 |
Why?
|
| Adolescent | 7 | 2024 | 2985 | 0.200 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2022 | 9 | 0.200 |
Why?
|
| Interleukin-4 | 2 | 2023 | 7 | 0.200 |
Why?
|
| Diarrhea | 2 | 1996 | 76 | 0.200 |
Why?
|
| Algorithms | 2 | 2021 | 106 | 0.200 |
Why?
|
| Genes, Viral | 2 | 1993 | 11 | 0.200 |
Why?
|
| Disease Outbreaks | 3 | 2015 | 111 | 0.190 |
Why?
|
| Anticoagulants | 2 | 2001 | 57 | 0.190 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 5 | 0.190 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2021 | 7 | 0.190 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2021 | 7 | 0.190 |
Why?
|
| Chloroquine | 1 | 2021 | 10 | 0.190 |
Why?
|
| Treatment Outcome | 3 | 2019 | 889 | 0.190 |
Why?
|
| Phylogeny | 6 | 2018 | 231 | 0.190 |
Why?
|
| Liver | 2 | 2019 | 74 | 0.180 |
Why?
|
| Interleukin-6 | 4 | 2024 | 51 | 0.180 |
Why?
|
| Down-Regulation | 1 | 2001 | 22 | 0.180 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2021 | 56 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 244 | 0.180 |
Why?
|
| Genome, Human | 1 | 2021 | 25 | 0.180 |
Why?
|
| Africa, Southern | 2 | 2015 | 91 | 0.180 |
Why?
|
| Latent Tuberculosis | 1 | 2020 | 45 | 0.170 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2000 | 2 | 0.170 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 5 | 0.170 |
Why?
|
| Specimen Handling | 1 | 2001 | 105 | 0.170 |
Why?
|
| South America | 1 | 2020 | 27 | 0.170 |
Why?
|
| CD3 Complex | 2 | 2010 | 14 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 132 | 0.170 |
Why?
|
| Family Characteristics | 1 | 2020 | 135 | 0.170 |
Why?
|
| 5' Untranslated Regions | 1 | 2019 | 7 | 0.170 |
Why?
|
| Genetic Carrier Screening | 1 | 2019 | 12 | 0.170 |
Why?
|
| Introns | 1 | 2019 | 13 | 0.170 |
Why?
|
| Genitalia | 1 | 2019 | 8 | 0.170 |
Why?
|
| Virus Shedding | 1 | 2019 | 24 | 0.170 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 29 | 0.160 |
Why?
|
| CD4 Antigens | 2 | 2012 | 49 | 0.160 |
Why?
|
| Plasma | 1 | 2019 | 39 | 0.160 |
Why?
|
| Donor Selection | 1 | 2019 | 7 | 0.160 |
Why?
|
| Immunogenetic Phenomena | 1 | 2019 | 7 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2019 | 18 | 0.160 |
Why?
|
| Immunoglobulin G | 2 | 2023 | 231 | 0.160 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 14 | 0.160 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 253 | 0.160 |
Why?
|
| In Vitro Techniques | 3 | 2006 | 54 | 0.160 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2019 | 5 | 0.160 |
Why?
|
| Phosphoproteins | 1 | 2019 | 10 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2019 | 179 | 0.160 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 20 | 0.160 |
Why?
|
| Immunophenotyping | 1 | 2019 | 24 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 20 | 0.160 |
Why?
|
| Transcription, Genetic | 2 | 1996 | 14 | 0.160 |
Why?
|
| Sequence Homology, Amino Acid | 5 | 2007 | 27 | 0.160 |
Why?
|
| Macrophage-1 Antigen | 1 | 1998 | 2 | 0.160 |
Why?
|
| Mucous Membrane | 1 | 2018 | 12 | 0.150 |
Why?
|
| HLA-DR Antigens | 1 | 1998 | 13 | 0.150 |
Why?
|
| Urban Population | 1 | 2000 | 257 | 0.150 |
Why?
|
| Temperature | 1 | 1998 | 56 | 0.150 |
Why?
|
| Receptors, Interleukin | 1 | 1998 | 1 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 77 | 0.150 |
Why?
|
| Sexual Partners | 1 | 2019 | 215 | 0.150 |
Why?
|
| Receptor, Anaphylatoxin C5a | 3 | 2004 | 4 | 0.150 |
Why?
|
| Adenovirus Infections, Human | 2 | 1996 | 3 | 0.150 |
Why?
|
| Lung | 3 | 2024 | 70 | 0.150 |
Why?
|
| Sequence Homology, Nucleic Acid | 4 | 2003 | 16 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 163 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2018 | 175 | 0.140 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2023 | 18 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 150 | 0.140 |
Why?
|
| Marriage | 1 | 2017 | 5 | 0.140 |
Why?
|
| Receptors, CXCR6 | 1 | 2017 | 3 | 0.140 |
Why?
|
| Virus Activation | 1 | 2017 | 1 | 0.140 |
Why?
|
| Chemokine CCL5 | 2 | 2007 | 9 | 0.140 |
Why?
|
| Alternative Splicing | 1 | 2017 | 4 | 0.140 |
Why?
|
| Animals | 5 | 2011 | 1081 | 0.140 |
Why?
|
| Sequence Alignment | 2 | 2008 | 59 | 0.130 |
Why?
|
| Genetic Loci | 1 | 2015 | 11 | 0.130 |
Why?
|
| Rift Valley fever virus | 2 | 2015 | 3 | 0.130 |
Why?
|
| Serum | 1 | 2015 | 9 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2023 | 44 | 0.130 |
Why?
|
| Gene Expression | 1 | 2015 | 43 | 0.130 |
Why?
|
| Hexuronic Acids | 1 | 2015 | 19 | 0.120 |
Why?
|
| Glucuronic Acid | 1 | 2015 | 19 | 0.120 |
Why?
|
| Microspheres | 1 | 2015 | 8 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 17 | 0.120 |
Why?
|
| Microbial Viability | 1 | 2015 | 11 | 0.120 |
Why?
|
| Disease Transmission, Infectious | 1 | 2015 | 39 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 73 | 0.120 |
Why?
|
| Blood Cells | 1 | 1995 | 4 | 0.120 |
Why?
|
| Dendritic Cells | 1 | 1995 | 4 | 0.120 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2022 | 8 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 370 | 0.120 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2015 | 103 | 0.110 |
Why?
|
| Virion | 2 | 2011 | 12 | 0.110 |
Why?
|
| DNA Replication | 1 | 1994 | 3 | 0.110 |
Why?
|
| Ligands | 2 | 2011 | 33 | 0.110 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 10 | 0.110 |
Why?
|
| Mutation | 4 | 2024 | 306 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2013 | 5 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2024 | 14 | 0.110 |
Why?
|
| Risk | 1 | 2013 | 87 | 0.110 |
Why?
|
| Population Surveillance | 2 | 2013 | 325 | 0.110 |
Why?
|
| Interferons | 1 | 1993 | 9 | 0.100 |
Why?
|
| Intestines | 1 | 1993 | 7 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 1999 | 32 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 107 | 0.100 |
Why?
|
| CD56 Antigen | 1 | 2012 | 5 | 0.100 |
Why?
|
| Adenoviridae Infections | 2 | 1989 | 2 | 0.100 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2015 | 196 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 115 | 0.100 |
Why?
|
| Africa | 3 | 2011 | 376 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2003 | 37 | 0.100 |
Why?
|
| Nucleocapsid | 1 | 2011 | 1 | 0.100 |
Why?
|
| Nucleocapsid Proteins | 1 | 2011 | 2 | 0.100 |
Why?
|
| Antigens, Fungal | 2 | 2023 | 9 | 0.100 |
Why?
|
| Disease | 1 | 2011 | 12 | 0.100 |
Why?
|
| HLA-DRB1 Chains | 1 | 2011 | 17 | 0.100 |
Why?
|
| Helper Viruses | 2 | 1990 | 5 | 0.090 |
Why?
|
| Binding Sites | 2 | 2003 | 43 | 0.090 |
Why?
|
| Aging | 1 | 2012 | 109 | 0.090 |
Why?
|
| Viral Vaccines | 1 | 2011 | 24 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 435 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 41 | 0.090 |
Why?
|
| Antigens, Viral | 3 | 2005 | 21 | 0.090 |
Why?
|
| Rotavirus Infections | 2 | 1989 | 46 | 0.090 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2005 | 155 | 0.090 |
Why?
|
| Adenoviridae | 2 | 1989 | 39 | 0.090 |
Why?
|
| Reference Values | 2 | 2001 | 64 | 0.090 |
Why?
|
| Prophages | 1 | 2010 | 3 | 0.090 |
Why?
|
| Vaginal Discharge | 1 | 2010 | 3 | 0.090 |
Why?
|
| DNA, Ribosomal | 1 | 2010 | 9 | 0.090 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2010 | 3 | 0.090 |
Why?
|
| CTLA-4 Antigen | 1 | 2010 | 5 | 0.090 |
Why?
|
| U937 Cells | 2 | 2000 | 4 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2022 | 107 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2010 | 45 | 0.090 |
Why?
|
| Antibodies | 1 | 2010 | 25 | 0.090 |
Why?
|
| Glucuronidase | 2 | 2001 | 2 | 0.090 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 20 | 0.090 |
Why?
|
| Edetic Acid | 2 | 2001 | 8 | 0.080 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2000 | 11 | 0.080 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2009 | 10 | 0.080 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2001 | 3 | 0.080 |
Why?
|
| Biological Assay | 1 | 2009 | 32 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 3 | 1998 | 142 | 0.080 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 6 | 0.080 |
Why?
|
| Phenotype | 2 | 2022 | 158 | 0.080 |
Why?
|
| Cell Line | 2 | 2000 | 93 | 0.070 |
Why?
|
| Prevalence | 3 | 2017 | 1192 | 0.070 |
Why?
|
| Muromegalovirus | 1 | 2007 | 1 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2007 | 10 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2007 | 9 | 0.070 |
Why?
|
| Peptides | 1 | 2007 | 40 | 0.070 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2007 | 118 | 0.070 |
Why?
|
| beta 2-Microglobulin | 1 | 2006 | 4 | 0.070 |
Why?
|
| Neopterin | 1 | 2006 | 4 | 0.070 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 14 | 0.070 |
Why?
|
| Mitogens | 1 | 2006 | 4 | 0.070 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2006 | 4 | 0.070 |
Why?
|
| Kinetics | 2 | 2020 | 65 | 0.070 |
Why?
|
| Immunologic Memory | 1 | 2006 | 15 | 0.060 |
Why?
|
| Urine | 1 | 2005 | 6 | 0.060 |
Why?
|
| Molecular Epidemiology | 1 | 2005 | 47 | 0.060 |
Why?
|
| Viral Fusion Proteins | 1 | 2005 | 13 | 0.060 |
Why?
|
| Pharmacogenomic Variants | 1 | 2025 | 6 | 0.060 |
Why?
|
| Vero Cells | 2 | 1996 | 6 | 0.060 |
Why?
|
| HIV Protease | 1 | 2024 | 22 | 0.060 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2024 | 41 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2024 | 6 | 0.060 |
Why?
|
| Restriction Mapping | 2 | 1996 | 3 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2A6 | 1 | 2023 | 3 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2023 | 16 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2023 | 17 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2023 | 2 | 0.050 |
Why?
|
| Cameroon | 1 | 2023 | 9 | 0.050 |
Why?
|
| Capsid | 2 | 1994 | 2 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2024 | 198 | 0.050 |
Why?
|
| Species Specificity | 2 | 1994 | 49 | 0.050 |
Why?
|
| Body Weight | 1 | 2024 | 111 | 0.050 |
Why?
|
| Mouth | 1 | 2023 | 8 | 0.050 |
Why?
|
| Feces | 2 | 1996 | 30 | 0.050 |
Why?
|
| Walk Test | 1 | 2023 | 2 | 0.050 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2023 | 2 | 0.050 |
Why?
|
| Proviruses | 1 | 2003 | 6 | 0.050 |
Why?
|
| Africa, Central | 1 | 2003 | 7 | 0.050 |
Why?
|
| Africa, Northern | 1 | 2003 | 5 | 0.050 |
Why?
|
| Africa, Western | 1 | 2003 | 8 | 0.050 |
Why?
|
| Africa, Eastern | 1 | 2003 | 17 | 0.050 |
Why?
|
| Child Development | 1 | 2024 | 93 | 0.050 |
Why?
|
| Fibroblasts | 2 | 2007 | 14 | 0.050 |
Why?
|
| Evolution, Molecular | 1 | 2003 | 60 | 0.050 |
Why?
|
| Heterosexuality | 2 | 2019 | 30 | 0.050 |
Why?
|
| Genes, pol | 1 | 2022 | 4 | 0.050 |
Why?
|
| NAD+ Nucleosidase | 1 | 2002 | 2 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 3 | 0.050 |
Why?
|
| Amino Acids | 1 | 2022 | 16 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2022 | 12 | 0.050 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2003 | 104 | 0.050 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2005 | 200 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2022 | 49 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 37 | 0.050 |
Why?
|
| DNA Primers | 3 | 2011 | 55 | 0.050 |
Why?
|
| Probability | 1 | 2001 | 27 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2001 | 1 | 0.050 |
Why?
|
| Tetanus Toxoid | 1 | 2001 | 14 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 106 | 0.050 |
Why?
|
| Forecasting | 1 | 2001 | 20 | 0.050 |
Why?
|
| Databases, Genetic | 1 | 2021 | 22 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 7 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2001 | 10 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2021 | 65 | 0.050 |
Why?
|
| Survival Rate | 1 | 2001 | 96 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2001 | 23 | 0.050 |
Why?
|
| Complement C5a, des-Arginine | 1 | 2001 | 1 | 0.050 |
Why?
|
| Sputum | 1 | 2022 | 135 | 0.050 |
Why?
|
| Zidovudine | 1 | 2001 | 59 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1993 | 6 | 0.040 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2020 | 1 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2020 | 4 | 0.040 |
Why?
|
| Lamivudine | 1 | 2001 | 89 | 0.040 |
Why?
|
| Tuberculin Test | 1 | 2020 | 49 | 0.040 |
Why?
|
| Cation Transport Proteins | 1 | 2000 | 3 | 0.040 |
Why?
|
| Lymphotoxin-alpha | 1 | 2000 | 2 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2000 | 12 | 0.040 |
Why?
|
| Acute Disease | 1 | 2000 | 105 | 0.040 |
Why?
|
| Virulence | 1 | 2000 | 25 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2000 | 23 | 0.040 |
Why?
|
| Heteroduplex Analysis | 1 | 2000 | 4 | 0.040 |
Why?
|
| Genes, gag | 1 | 2000 | 6 | 0.040 |
Why?
|
| Genes, env | 1 | 2000 | 9 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2000 | 36 | 0.040 |
Why?
|
| Fluconazole | 1 | 2020 | 17 | 0.040 |
Why?
|
| Meningitis, Aseptic | 1 | 2000 | 2 | 0.040 |
Why?
|
| Cell Aggregation | 1 | 2000 | 2 | 0.040 |
Why?
|
| Inflammation | 1 | 2020 | 104 | 0.040 |
Why?
|
| DNA Probes | 2 | 2009 | 3 | 0.040 |
Why?
|
| Meningitis, Bacterial | 1 | 2000 | 38 | 0.040 |
Why?
|
| Mice | 2 | 2011 | 135 | 0.040 |
Why?
|
| Blood Donors | 1 | 1999 | 19 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2019 | 17 | 0.040 |
Why?
|
| Graft Survival | 1 | 2019 | 40 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2019 | 22 | 0.040 |
Why?
|
| Critical Illness | 1 | 2019 | 44 | 0.040 |
Why?
|
| Heparin | 1 | 1998 | 5 | 0.040 |
Why?
|
| Neutrophil Activation | 1 | 1998 | 12 | 0.040 |
Why?
|
| Incidence | 1 | 2020 | 685 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2021 | 799 | 0.040 |
Why?
|
| Respiratory Burst | 1 | 1998 | 2 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 20 | 0.040 |
Why?
|
| Phagocytosis | 1 | 1998 | 15 | 0.040 |
Why?
|
| HIV Core Protein p24 | 1 | 1998 | 18 | 0.040 |
Why?
|
| Calcium | 1 | 1998 | 49 | 0.040 |
Why?
|
| Rotavirus | 2 | 1989 | 29 | 0.040 |
Why?
|
| Seasons | 3 | 2001 | 154 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2017 | 62 | 0.030 |
Why?
|
| Pneumonia | 1 | 1998 | 131 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2016 | 7 | 0.030 |
Why?
|
| Conjunctiva | 1 | 1996 | 2 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2017 | 45 | 0.030 |
Why?
|
| Templates, Genetic | 1 | 1996 | 2 | 0.030 |
Why?
|
| HeLa Cells | 1 | 1996 | 15 | 0.030 |
Why?
|
| Cytological Techniques | 1 | 2015 | 1 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2015 | 19 | 0.030 |
Why?
|
| Complement Membrane Attack Complex | 1 | 1995 | 1 | 0.030 |
Why?
|
| Cell Separation | 1 | 1995 | 6 | 0.030 |
Why?
|
| Viral Structural Proteins | 1 | 1994 | 1 | 0.030 |
Why?
|
| Serial Passage | 1 | 1994 | 5 | 0.030 |
Why?
|
| Superinfection | 1 | 1994 | 8 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1994 | 8 | 0.030 |
Why?
|
| Cervix Uteri | 1 | 2014 | 22 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 1993 | 7 | 0.030 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2014 | 36 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 2 | 0.030 |
Why?
|
| Microvilli | 1 | 1993 | 2 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 1993 | 6 | 0.030 |
Why?
|
| Fetus | 1 | 1993 | 8 | 0.030 |
Why?
|
| Spleen | 1 | 2011 | 9 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 11 | 0.020 |
Why?
|
| Genetics, Medical | 1 | 2011 | 21 | 0.020 |
Why?
|
| Immunization | 1 | 2011 | 63 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 6 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 1990 | 26 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 1990 | 16 | 0.020 |
Why?
|
| Virus Cultivation | 1 | 1990 | 9 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Terminal Repeat Sequences | 1 | 2009 | 1 | 0.020 |
Why?
|
| Population Groups | 1 | 2009 | 9 | 0.020 |
Why?
|
| United Kingdom | 1 | 2009 | 33 | 0.020 |
Why?
|
| Reference Standards | 1 | 2009 | 29 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 65 | 0.020 |
Why?
|
| Campylobacter | 1 | 1989 | 1 | 0.020 |
Why?
|
| Coronaviridae | 1 | 1989 | 1 | 0.020 |
Why?
|
| Culture Techniques | 1 | 1989 | 2 | 0.020 |
Why?
|
| Immunoblotting | 1 | 1989 | 2 | 0.020 |
Why?
|
| Tropical Climate | 1 | 1989 | 4 | 0.020 |
Why?
|
| Enterobacteriaceae | 1 | 1989 | 11 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2009 | 22 | 0.020 |
Why?
|
| Serotyping | 1 | 1989 | 66 | 0.020 |
Why?
|
| Vaccination | 1 | 2011 | 365 | 0.020 |
Why?
|
| Drosophila | 1 | 2007 | 2 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 9 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2007 | 14 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2007 | 7 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2007 | 12 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2007 | 24 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2007 | 84 | 0.020 |
Why?
|
| Gastroenteritis | 1 | 1986 | 22 | 0.020 |
Why?
|
| Rural Population | 1 | 1989 | 654 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2005 | 108 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2002 | 2 | 0.010 |
Why?
|
| Sequence Analysis, RNA | 1 | 2002 | 17 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2002 | 7 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 11 | 0.010 |
Why?
|
| Prognosis | 1 | 2002 | 199 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 188 | 0.010 |
Why?
|
| Japan | 1 | 2000 | 7 | 0.010 |
Why?
|
| Homosexuality | 1 | 2000 | 5 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2000 | 13 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2000 | 11 | 0.010 |
Why?
|
| Spinal Puncture | 1 | 2000 | 4 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 25 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 38 | 0.010 |
Why?
|
| Sex Work | 1 | 2000 | 39 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 63 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2000 | 64 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 2000 | 35 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 1998 | 23 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1998 | 24 | 0.010 |
Why?
|